EMA Drops Req’s for Testing Untreated Patients in Hemophilia

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency revised two guidelines on the development and labeling of factor VIII products used to treat hemophilia A, removing requirements for sponsors to conduct clinical trials in previously untreated patients.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor